All In Biotech

Drug Trial Radar · NCT05326412

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

49

Actual

Start

May 19, 2022

Primary completion

Mar 5, 2025

Study completion Jul 25, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Apr 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years. This study consisted of participants who had been on a standard-of-care (SoC) mono (long-acting β2-agonist \[LABA\]) or long-acting muscarinic antagonist \[LAMA\]), double (inhaled corticosteroid \[ICS\] + LABA, LABA + LAMA or ICS + LAMA), or triple (ICS + LABA + LAMA) controller therapy for COPD for at least 3 months prior to Screening (Visit 1) with stable dose and regimen for controller therapy for ≥1 month prior to Screening (Visit 1) and during the screening period. Participants would stay on their established controller medications for COPD throughout the duration of the study, with the exception of systemic corticosteroids and/or antibiotics used for acute exacerbation of COPD (AECOPD). Part A would consist of participants who were former smokers with COPD; Part B would consist of participants who were current smokers with COPD. The total study duration for each part (Part A and Part B) was approximately 36 weeks: * 4-week screening period * 12-week treatment period * 20-week followup period

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Itepekimab SAR440340Drug

    Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Endobronchial Biopsies in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12Time frame: Baseline (Week 0) and Week 12
  2. Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Bronchial Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12Time frame: Baseline (Week 0) and Week 12
  3. Change From Baseline in Itepekimab Pharmacodynamic Normalized Enrichment Score Derived From Former Smokers in Nasal Brushings in Current Smokers With Chronic Obstructive Pulmonary Disease at Week 12Time frame: Baseline (Week 0) and Week 12

Locations

23 sites in 7 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center - Harbor- Site Number : 8400006

    Torrance, California

  • National Jewish Health Medical Center- Site Number : 8400012

    Denver, Colorado

  • University of Miami UHealth Tower- Site Number : 8400015

    Miami, Florida

  • University of Kansas Medical Center- Site Number : 8400004

    Kansas City, Missouri

  • Allergy, Asthma and Clinical Research- Site Number : 8400010

    Oklahoma City, Oklahoma

  • Clinical Research Associates of Central PA - Dubois- Site Number : 8400011

    DuBois, Pennsylvania

  • University of Texas - Southwestern Medical Center- Site Number : 8400014

    Dallas, Texas

  • Investigational Site Number : 0560001

    Edegem, Belgium

  • Hospital Beneficência Portuguesa de São Paulo- Site Number : 0760005

    São Paulo, Brazil

  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760003

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital e Maternidade Celso Pierro - PUC-Campinas- Site Number : 0760004

    Campinas, São Paulo, Brazil

  • Integral Pesquisa e Ensino- Site Number : 0760006

    Votuporanga, São Paulo, Brazil

  • Investigational Site Number : 2080003

    Aalborg, Denmark

  • Investigational Site Number : 2080001

    Copenhagen, Denmark

  • Investigational Site Number : 2080002

    Hvidovre, Denmark

  • Investigational Site Number : 2760005

    Freiburg im Breisgau, Germany

  • Investigational Site Number : 2760001

    Großhansdorf, Germany

  • Investigational Site Number : 2760004

    Peine, Germany

  • Investigational Site Number : 5280001

    Groningen, Netherlands

  • Investigational Site Number : 8260002

    Liverpool, United Kingdom

  • Investigational Site Number : 8260003

    Wythenshawe, Cheshire West And Chester, United Kingdom

  • Investigational Site Number : 8260004

    London, London, City of, United Kingdom

  • Investigational Site Number : 8260001

    Nottingham, Nottinghamshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.